YESTAR HEALTH (02393) has announced its financial performance for 2025. Revenue from continuing operations amounted to approximately RMB 1.49 billion, representing a decrease of 38.17% compared to the previous year. The company recorded a net loss attributable to owners of RMB 75.03 million, a reversal from a profit in the prior year. The loss per share was 3.22 cents.